首页> 美国卫生研究院文献>Diabetes Care >Serotonin 5-HT3 Receptor Antagonist for Treatment of Severe Diabetic Diarrhea
【2h】

Serotonin 5-HT3 Receptor Antagonist for Treatment of Severe Diabetic Diarrhea

机译:5-羟色胺5-HT3受体拮抗剂治疗严重糖尿病性腹泻

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Diabetic diarrhea is a troublesome gastrointestinal complication of diabetes. This condition persists for several weeks to months, and it frequently accompanies fecal incontinence. The cause of diabetic diarrhea is not fully understood, but autonomic neuropathy is thought to be an underlying mechanism ( ). Parenteral somatostatin analog octreotide has been shown to be useful in the treatment of severe long-standing diabetic diarrhea ( ). Selective serotonin 5-hydroxy tryptamine type 3 (HT3) receptor antagonist, which was developed as an antiemetic in cancer chemotherapy, prolongs colonic transit, inhibits small bowel secretion, and decreases colonic compliance ( ). Here, we report the underlying mechanism of ramosetron ( ), a selective serotonin 5-HT3 receptor antagonist, for the treatment of severe diabetic diarrhea.
机译:糖尿病性腹泻是糖尿病的胃肠道并发症。这种情况持续数周至数月,并且经常伴有大便失禁。糖尿病性腹泻的原因尚不完全清楚,但自主神经病被认为是其潜在机制()。肠胃外生长抑素类似物奥曲肽已显示可用于治疗严重的长期糖尿病性腹泻()。选择性5-羟色胺5-羟基色胺3型(HT3)受体拮抗剂在癌症化疗中作为止吐药开发,可延长结肠运输,抑制小肠分泌并降低结肠顺应性()。在这里,我们报告了选择性血清素5-HT3受体拮抗剂雷莫司琼()的治疗严重糖尿病性腹泻的潜在机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号